about
Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to dateLifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependenceKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Inflammation and pharmacokinetics: potential implications for HIV-infection.Changes in Bone Mineral Density, Body Composition, Vitamin D Status, and Mineral Metabolism in Urban HIV-Positive South African Women Over 12 Months.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care.Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence.Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.Management of Reduced Bone Mineral Density in HIV: Pharmacological Challenges and the Role of Exercise
P2860
Q28079025-8E266042-3342-47D7-ABDF-2168856BEF48Q33627227-9C894FB2-7D0A-49EB-AF88-46D3990682F2Q34536677-9C8F9DB3-8E01-48BE-AD44-66F99EA14C3CQ38740792-0D39EEF2-B63A-4C5A-B03B-4F965599B3B9Q38859466-9483B21B-3617-4608-9375-4A6051963671Q38984695-5905F6E5-A36C-41B9-BD56-C2A1781FDAE5Q38985811-F3DDCBF0-B889-43DE-9E92-30F4B0603BA0Q39145435-4CB5BAF3-1B78-4DDA-B022-951ADE7E2BD0Q43075772-26BFACC7-4944-4159-8686-E5AA9068D74CQ45170011-394F8190-D834-49CE-8798-4663A39982AFQ52664377-9F74E345-A8EB-42CE-A7F4-B97F315A86AAQ55280381-63079C9A-1F29-4742-9462-385F19CA2734Q56984507-1B570E58-045B-4B8B-9161-B0C1C3930C63
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tenofovir and bone health.
@en
type
label
Tenofovir and bone health.
@en
prefLabel
Tenofovir and bone health.
@en
P2860
P1476
Tenofovir and bone health.
@en
P2093
Aoife G Cotter
Philip M Grant
P2860
P304
P356
10.1097/COH.0000000000000248
P577
2016-02-06T00:00:00Z